Chemotherapy in metastatic renal cell cancer.
Currently, there is no standard treatment for patients with advanced renal cell carcinoma (RCC) who do not respond to or progress after transient remission to first-line immunotherapy. At the end of the 1990s, no single chemotherapeutic drug, alone or in combination with interleukin-2 (IL-2) or interferon-alfa (IFN), had shown activity beyond the one expected by immunotherapy alone. New drugs on the market such as the pyrimidine analog gemcitabine or taxane-based chemotherapeutics may show promising tumor activity in combination with targeted therapy, but this has to be substantiated in upcoming trials. There is a great need to develop effective systemic therapy for advanced MRCC and to evaluate the efficacy of new drugs in clinical trials.
Lilleby
Wolfgang
W
Department of Medical Oncology and Radiotherapy, The Norwegian Radium University Hospital, Oslo, Norway. wolfgang.lilleby@klinmed.uio.no
Fosså
Sophie D
SD
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary
Cancer Chemother Pharmacol. 2002 Aug;50(2):160-2
12172983
J Clin Oncol. 1990 Sep;8(9):1504-13
2144018
J Urol. 1993 Aug;150(2 Pt 1):463-6
8326579
Cancer Res. 2002 Jun 1;62(11):3014-9
12036906
J Urol. 2003 Oct;170(4 Pt 1):1141-5
14501711
J Clin Oncol. 1999 Jul;17 (7):2039-43
10561255
Cancer Chemother Pharmacol. 2000;46(1):27-34
10912574
Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41
11395851
Cancer. 2003 Nov 1;98(9):1837-41
14584064
J Clin Oncol. 2000 Jun;18(12):2419-26
10856102
Cancer Chemother Pharmacol. 1996;37(5):491-5
8599874
Cancer Treat Res. 1996;87:3-38
8886447
J Clin Oncol. 2004 Apr 1;22(7):1188-94
14981107
Cancer. 2004 May 15;100(10):2132-8
15139055
Chem Biol Interact. 1998 Apr 24;111-112:1-14
9679538
Eur J Cancer. 1992;28A(4-5):878-80
1524914
J Clin Oncol. 2003 Jul 1;21(13):2574-82
12829678
Semin Oncol. 1995 Feb;22(1):42-60
7855619
Oncology. 2002;63(2):130-8
12239447
Eur J Cancer. 1994;30A(8):1064-7
7654430
J Clin Oncol. 2003 Apr 15;21(8):1524-9
12697876
Nat Genet. 1994 May;7(1):85-90
7915601
World J Urol. 1994;12(4):214-23
7820144
Br J Cancer. 2002 Aug 27;87(5):497-501
12189543
Br J Cancer. 2000 Sep;83(5):583-7
10944596
Oncology. 2003;64(1):25-7
12457028
Cancer. 2003 Jul 1;98 (1):61-5
12833456
Cancer Chemother Pharmacol. 1997;39(6):547-51
9118468
J Clin Oncol. 1997 Dec;15(12):3507-14
9396404
Cancer. 2001 Aug 1;92(3):519-23
11505395
Cancer. 2004 Aug 1;101(3):533-40
15274066
Bull Cancer. 2000 Dec;87(12):881-6
11174117
Invest New Drugs. 2002 Nov;20(4):413-7
12448659
Urol Int. 1990;45(3):170-6
1971972
J Urol. 2000 Feb;163(2):408-17
10647643
Ann Oncol. 1991 Jun;2(6):443
1768632
Eur J Cancer. 2002 Sep;38(14):1817-23
12204662
J Clin Oncol. 1997 Nov;15(11):3394-8
9363871
J Clin Oncol. 2000 Aug;18(16):2972-80
10944130
J Cancer Res Clin Oncol. 1995;121 Suppl 3:R11-6
8698736
Invest New Drugs. 2001;19(4):317-20
11561691
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
990323
Eur J Cancer. 1994;30A(9):1310-4
7999419
J Interferon Cytokine Res. 2004 Jan;24(1):37-41
14980083
Cancer. 2002 May 15;94(10):2602-9
12173327
Am J Clin Oncol. 2000 Jun;23(3):288-9
10857895
J Clin Oncol. 2000 Dec 15;18(24):4009-15
11118461
Cancer. 2002 Oct 15;95(8):1644-9
12365011
Urology. 2001 Apr;57(4):650-4
11306370
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92
9653127
Eur Urol. 2003 Jul;44(1):65-75
12814677
J Clin Oncol. 2003 Aug 15;21(16):3127-32
12915604